Karen L. Lindsay

Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa

Gary L. Davis, Luis A. Balart, Eugene R. Schiff et al. · New England Journal of Medicine · 1989 · 1.7K citations

Pharmacy, Internal Medicine, Pharmacotherapy +14

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C

Thierry Poynard, John G. McHutchison, Michael P. Manns et al. · Gastroenterology · 2002 · 1.1K citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +16

Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C

John G. McHutchison, Michael P. Manns, Keyur Patel et al. · Gastroenterology · 2002 · 977 citations · Full text

Pharmacy, Pharmacotherapy, Hepatitis Pharmacotherapy +12

A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B

Robert P. Perrillo, Henry C. Bodenheimer, Karen L. Lindsay et al. · New England Journal of Medicine · 1990 · 850 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Eric Lawitz, Mark Sulkowski, Reem Ghalib et al. · The Lancet · 2014 · 818 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16